<p>Alector, Inc.（纳斯达克代码：ALEC - 获取免费报告）首席执行官 Arnon Rosenthal 于 12 月 3 日星期三出售了 104,347 股公司的股票。股票以平均价格 1.12 美元出售，总交易额为 116,868.64 美元。出售后，首席执行官直接持有公司 2,420,040 股，价值 2,710,444.80 美元。此次交易代表其持股比例减少了 4.13%。该出售在与证券交易委员会的法律文件中披露，相关文件可通过此链接访问。</p>
<h2>Alector 价格表现</h2>
<ul>
<li>这些生物技术公司针对多种神经退行性疾病</li>
</ul>
<p>在周三的交易中，ALEC 的股价保持在 1.14 美元。公司股票的交易量为 2,416,619 股，而其平均交易量为 1,542,667 股。该公司的债务与股本比率为 0.17，流动比率为 3.76，速动比率为 3.76。Alector, Inc.的 12 个月最低价为 0.87 美元，最高价为 3.40 美元。该股票的 50 日移动平均价为 2.01 美元，200 日移动平均价为 1.94 美元。该股票的市值为 1.2443 亿美元，市盈率为-1.07，贝塔值为 0.67。</p>
<p>Alector（纳斯达克代码：ALEC - 获取免费报告）最近于 11 月 6 日星期四公布了季度财报。公司报告该季度每股收益为（0.34 美元），超出市场共识预期的（0.42 美元）0.08 美元。Alector 的股本回报率为-123.02%，净利润率为-156.03%。该季度公司的收入为 326 万美元，而市场共识预期为 349 万美元。股票分析师预测 Alector, Inc.在本年度将发布-1.88 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近调整了对该股票的持有。先锋集团（Vanguard Group Inc.）在第三季度增持了 Alector 的股份，增幅为 0.8%。先锋集团目前持有 6,034,659 股公司股票，价值 17,863,000 美元，此前在上个季度又购买了 46,955 股。Acadian Asset Management LLC 在第二季度增持了 Alector 的股份，增幅为 50.7%。Acadian Asset Management LLC 目前持有 2,170,388 股公司股票，价值 3,033,000 美元，此前在上个季度又收购了 729,727 股。Geode Capital Management LLC 在第二季度增持了 Alector 的股份，增幅为 1.0%。Geode Capital Management LLC 目前持有 1,982,068 股公司股票，价值 2,775,000 美元，此前在上个季度又收购了 19,970 股。Jacobs Levy Equity Management Inc.在第一季度增持了 Alector 的股份，增幅为 25.9%。Jacobs Levy Equity Management Inc.目前持有 1,334,032 股公司股票，价值 1,641,000 美元，此前在上个季度又收购了 274,341 股。最后，Millennium Management LLC 在第三季度增持了 Alector 的股份，增幅为 181.2%。Millennium Management LLC 目前持有 1,155,027 股公司股票，价值 3,419,000 美元，此前在上个季度又购买了 744,224 股。机构投资者和对冲基金持有公司 85.83% 的股票。</p>
<h2>分析师评级调整</h2>
<p>几位股票分析师最近对 ALEC 股票发表了看法。HC Wainwright 将 Alector 的目标价格从 10.00 美元下调至 5.00 美元，并在 10 月 22 日星期三的报告中给予该公司 “买入” 评级。华尔街 Zen 在 11 月 28 日星期五的报告中将 Alector 的评级从 “持有” 下调至 “卖出”。瑞穗（Mizuho）在 10 月 22 日星期三的研究报告中对 Alector 设定了 1.50 美元的价格目标，并给予该股票 “中性” 评级。Cantor Fitzgerald 在 10 月 22 日星期三的研究报告中将 Alector 的评级从 “增持” 下调至 “中性”。最后，William Blair 在 10 月 22 日星期三的研究报告中将 Alector 的评级从 “跑赢大盘” 下调至 “市场表现”。一位研究分析师对该股票给予了 “买入” 评级，七位分析师给予了 “持有” 评级，三位分析师对该公司的股票给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “减持”，共识目标价格为 3.00 美元。</p>
<p><strong>阅读我们关于 ALEC 的最新报告</strong></p>
<h2>关于 Alector</h2>
<p>（获取免费报告）</p>
<p>Alector, Inc.是一家临床阶段的生物制药公司，开发用于治疗神经退行性疾病的疗法。其产品包括 AL001，这是一种与多种神经退行性疾病相关的免疫活性，目前正在进行针对额颞叶痴呆、阿尔茨海默病、帕金森病和肌萎缩侧索硬化症的第三阶段临床试验；以及 AL101，目前正在进行针对阿尔茨海默病和帕金森病等神经退行性疾病的第一阶段临床试验。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Alector</li>
<li>交通运输股票投资</li>
<li>三只有望受益于谷歌 AI 突破的股票</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>超越 NVIDIA：五只将在 2026 年主导市场的半导体股票</li>
<li>投资者如何识别并成功交易缺口下跌的股票</li>
<li>三只你会希望在 2026 年前购买的股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Alector 吗？</h2>
<p>在你考虑 Alector 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Alector 并不在名单上。</p>
<p>虽然 Alector 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ALEC

<p>Alector 首席执行官 Arnon Rosenthal 以每股 1.12 美元的价格出售了 104,347 股公司股票，总计 116,868.64 美元。这次出售使他的持股比例减少了 4.13%，目前持有 2,420,040 股。该交易已在 SEC 文件中披露。Alector 的股票保持在 1.14 美元，市值为 1.2443 亿美元。分析师的评级意见不一，普遍共识为 “减持”，目标价格为 3.00 美元</p>

<p>Alector, Inc. (NASDAQ:ALEC - Get Free Report) CEO Arnon Rosenthal sold 104,347 shares of the business's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total transaction of $116,868.64. Following the sale, the chief executive officer directly owned 2,420,040 shares in the company, valued at $2,710,444.80. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this link.</p>
<div class="lb-trans"><p>Alector, Inc.（纳斯达克代码：ALEC - 获取免费报告）首席执行官 Arnon Rosenthal 于 12 月 3 日星期三出售了 104,347 股公司的股票。股票以平均价格 1.12 美元出售，总交易额为 116,868.64 美元。出售后，首席执行官直接持有公司 2,420,040 股，价值 2,710,444.80 美元。此次交易代表其持股比例减少了 4.13%。该出售在与证券交易委员会的法律文件中披露，相关文件可通过此链接访问。</p>
</div><h2>Alector Price Performance</h2>
<div class="lb-trans"><h2>Alector 价格表现</h2>
</div><ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><ul>
<li>这些生物技术公司针对多种神经退行性疾病</li>
</ul>
</div><p>ALEC remained flat at $1.14 during trading on Wednesday. 2,416,619 shares of the company's stock were exchanged, compared to its average volume of 1,542,667. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.76 and a quick ratio of 3.76. Alector, Inc. has a 12 month low of $0.87 and a 12 month high of $3.40. The stock has a 50-day moving average of $2.01 and a two-hundred day moving average of $1.94. The stock has a market capitalization of $124.43 million, a PE ratio of -1.07 and a beta of 0.67.</p>
<div class="lb-trans"><p>在周三的交易中，ALEC 的股价保持在 1.14 美元。公司股票的交易量为 2,416,619 股，而其平均交易量为 1,542,667 股。该公司的债务与股本比率为 0.17，流动比率为 3.76，速动比率为 3.76。Alector, Inc.的 12 个月最低价为 0.87 美元，最高价为 3.40 美元。该股票的 50 日移动平均价为 2.01 美元，200 日移动平均价为 1.94 美元。该股票的市值为 1.2443 亿美元，市盈率为-1.07，贝塔值为 0.67。</p>
</div><p>Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.08. Alector had a negative return on equity of 123.02% and a negative net margin of 156.03%.The company had revenue of $3.26 million for the quarter, compared to the consensus estimate of $3.49 million. Equities analysts forecast that Alector, Inc. will post -1.88 EPS for the current year.</p>
<div class="lb-trans"><p>Alector（纳斯达克代码：ALEC - 获取免费报告）最近于 11 月 6 日星期四公布了季度财报。公司报告该季度每股收益为（0.34 美元），超出市场共识预期的（0.42 美元）0.08 美元。Alector 的股本回报率为-123.02%，净利润率为-156.03%。该季度公司的收入为 326 万美元，而市场共识预期为 349 万美元。股票分析师预测 Alector, Inc.在本年度将发布-1.88 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Alector by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 6,034,659 shares of the company's stock worth $17,863,000 after buying an additional 46,955 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Alector by 50.7% during the second quarter. Acadian Asset Management LLC now owns 2,170,388 shares of the company's stock valued at $3,033,000 after acquiring an additional 729,727 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Alector by 1.0% in the second quarter. Geode Capital Management LLC now owns 1,982,068 shares of the company's stock valued at $2,775,000 after acquiring an additional 19,970 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Alector by 25.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company's stock worth $1,641,000 after acquiring an additional 274,341 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Alector by 181.2% during the third quarter. Millennium Management LLC now owns 1,155,027 shares of the company's stock worth $3,419,000 after purchasing an additional 744,224 shares in the last quarter. Institutional investors and hedge funds own 85.83% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该股票的持有。先锋集团（Vanguard Group Inc.）在第三季度增持了 Alector 的股份，增幅为 0.8%。先锋集团目前持有 6,034,659 股公司股票，价值 17,863,000 美元，此前在上个季度又购买了 46,955 股。Acadian Asset Management LLC 在第二季度增持了 Alector 的股份，增幅为 50.7%。Acadian Asset Management LLC 目前持有 2,170,388 股公司股票，价值 3,033,000 美元，此前在上个季度又收购了 729,727 股。Geode Capital Management LLC 在第二季度增持了 Alector 的股份，增幅为 1.0%。Geode Capital Management LLC 目前持有 1,982,068 股公司股票，价值 2,775,000 美元，此前在上个季度又收购了 19,970 股。Jacobs Levy Equity Management Inc.在第一季度增持了 Alector 的股份，增幅为 25.9%。Jacobs Levy Equity Management Inc.目前持有 1,334,032 股公司股票，价值 1,641,000 美元，此前在上个季度又收购了 274,341 股。最后，Millennium Management LLC 在第三季度增持了 Alector 的股份，增幅为 181.2%。Millennium Management LLC 目前持有 1,155,027 股公司股票，价值 3,419,000 美元，此前在上个季度又购买了 744,224 股。机构投资者和对冲基金持有公司 85.83% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several equities analysts have recently weighed in on ALEC shares. HC Wainwright cut their target price on shares of Alector from $10.00 to $5.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, October 22nd. Wall Street Zen cut shares of Alector from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Friday, November 28th. Mizuho set a $1.50 price objective on shares of Alector and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, October 22nd. Cantor Fitzgerald lowered shares of Alector from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating in a research note on Wednesday, October 22nd. Finally, William Blair cut Alector from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Reduce&#34; and a consensus price target of $3.00.</p>
<div class="lb-trans"><p>几位股票分析师最近对 ALEC 股票发表了看法。HC Wainwright 将 Alector 的目标价格从 10.00 美元下调至 5.00 美元，并在 10 月 22 日星期三的报告中给予该公司 “买入” 评级。华尔街 Zen 在 11 月 28 日星期五的报告中将 Alector 的评级从 “持有” 下调至 “卖出”。瑞穗（Mizuho）在 10 月 22 日星期三的研究报告中对 Alector 设定了 1.50 美元的价格目标，并给予该股票 “中性” 评级。Cantor Fitzgerald 在 10 月 22 日星期三的研究报告中将 Alector 的评级从 “增持” 下调至 “中性”。最后，William Blair 在 10 月 22 日星期三的研究报告中将 Alector 的评级从 “跑赢大盘” 下调至 “市场表现”。一位研究分析师对该股票给予了 “买入” 评级，七位分析师给予了 “持有” 评级，三位分析师对该公司的股票给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “减持”，共识目标价格为 3.00 美元。</p>
</div><p><strong>Read Our Latest Report on ALEC</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ALEC 的最新报告</strong></p>
</div><h2>About Alector</h2>
<div class="lb-trans"><h2>关于 Alector</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.</p>
<div class="lb-trans"><p>Alector, Inc.是一家临床阶段的生物制药公司，开发用于治疗神经退行性疾病的疗法。其产品包括 AL001，这是一种与多种神经退行性疾病相关的免疫活性，目前正在进行针对额颞叶痴呆、阿尔茨海默病、帕金森病和肌萎缩侧索硬化症的第三阶段临床试验；以及 AL101，目前正在进行针对阿尔茨海默病和帕金森病等神经退行性疾病的第一阶段临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Alector</li>
<li>Transportation Stocks Investing</li>
<li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li>
<li>How to Short a Stock in 5 Easy Steps</li>
<li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>3 Stocks You’ll Wish You Bought Before 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Alector</li>
<li>交通运输股票投资</li>
<li>三只有望受益于谷歌 AI 突破的股票</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>超越 NVIDIA：五只将在 2026 年主导市场的半导体股票</li>
<li>投资者如何识别并成功交易缺口下跌的股票</li>
<li>三只你会希望在 2026 年前购买的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alector Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Alector 吗？</h2>
</div><p>Before you consider Alector, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Alector 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alector wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Alector 并不在名单上。</p>
</div><p>While Alector currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alector 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Arnon Rosenthal 出售了 104,347 股 Alector（NASDAQ:ALEC）的股票